OHARA Pharmaceutical Co.,Ltd.


HOME into Corporate profile into Outline of our pipeline

Corporate profile

Outline of Our Pipeline

Currently, we are developing four new drugs to treat childhood cancers. Of these drugs, we filed a New Drug Application for Crisantaspase, an antineoplastic enzyme preparation, in December 2015. We continue to strive to enhance our orphan drug pipeline, particularly against childhood cancers, in which large pharmaceutical companies are reluctant to be involved. Furthermore, we are committed to addressing unmet medical needs through drug development applying methods in epigenetics.

Progress chart of Pipeline